Loading page
Loading page
Loading substance route
Take on an empty stomach to increase absorption rate.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
High abuse potential with significant risk of psychological dependence. Amobarbital was widely misused recreationally, known on the street as 'Blue Heavens,' 'blue angels,' and 'blue devils,' and is classified as habit-forming.
Physical dependence develops with extended use. Withdrawal mimics delirium tremens and may be life-threatening, requiring medical supervision for discontinuation.
Severe overdose may result in death without intervention. The combination of amobarbital with alcohol has resulted in documented fatalities, including the death of actor Robert Walker in 1951 after receiving amobarbital while allegedly drinking.
| Species | Route | Value |
|---|---|---|
| mouse | subcutaneous | 212 mg/kg |
Amobarbital was first synthesized in Germany in 1923, emerging as a short to intermediate acting barbiturate derivative. The compound gained commercial prominence through Eli Lilly and Company, which manufactured it in the United States under the brand name Amytal. The medication was distinctively…
Previously marketed as combination products (Tuinal) containing amobarbital sodium with secobarbital sodium. These products were discontinued in 2004. Current status follows standard controlled substance scheduling for barbiturates.
Classified as 'Approved' and 'Illicit' in pharmaceutical databases, indicating recognized medical use alongside controlled substance status. Marketed as Amytal Sodium, a prescription injectable product for intramuscular and intravenous administration.
12 sources cited